Objective:To explore the effect of sodium valproate retard tablet on the oxidative stress system, cognitive function, and thyroid hormone level in patients with epilepsy.Methods:A total of 68 patients with epilepsy we...Objective:To explore the effect of sodium valproate retard tablet on the oxidative stress system, cognitive function, and thyroid hormone level in patients with epilepsy.Methods:A total of 68 patients with epilepsy were included in the study and randomized into the treatment group and the control group with 34 cases in each group. The patients in the treatment group were given sodium valproate retard tablets, while the patients in the control group were given carbamazepine. The patients in the two groups were treated continuously for 6 months. The oxidative stress indicators and thyroid hormone level before and after treatment in the two groups were detected and compared. MMSE was used to evaluate the cognitive function in the two groups.Results: MPO, SOD, CAT, and GSH-Px levels after treatment in the two groups were significantly reduced when compared with before treatment, while MDA level was significantly elevated. The improvement of the above indicators after treatment in the treatment group was significantly superior to that in the control group. FT3 and FT4 levels after treatment in the control group were significantly reduced when compared with before treatment, but were significantly lower than those in the treatment group. MMSE score 3 and 6 months after treatment in the two groups was significantly elevated when compared with before treatment. MMSE score at each timing point after treatment in the treatment group was significantly higher than that in the control group.Conclusions: The sodium valproate has a small effect on the balance of oxidation and anti-oxidation in patients with epilepsy, and can significantly improve the cognitive function.展开更多
文摘Objective:To explore the effect of sodium valproate retard tablet on the oxidative stress system, cognitive function, and thyroid hormone level in patients with epilepsy.Methods:A total of 68 patients with epilepsy were included in the study and randomized into the treatment group and the control group with 34 cases in each group. The patients in the treatment group were given sodium valproate retard tablets, while the patients in the control group were given carbamazepine. The patients in the two groups were treated continuously for 6 months. The oxidative stress indicators and thyroid hormone level before and after treatment in the two groups were detected and compared. MMSE was used to evaluate the cognitive function in the two groups.Results: MPO, SOD, CAT, and GSH-Px levels after treatment in the two groups were significantly reduced when compared with before treatment, while MDA level was significantly elevated. The improvement of the above indicators after treatment in the treatment group was significantly superior to that in the control group. FT3 and FT4 levels after treatment in the control group were significantly reduced when compared with before treatment, but were significantly lower than those in the treatment group. MMSE score 3 and 6 months after treatment in the two groups was significantly elevated when compared with before treatment. MMSE score at each timing point after treatment in the treatment group was significantly higher than that in the control group.Conclusions: The sodium valproate has a small effect on the balance of oxidation and anti-oxidation in patients with epilepsy, and can significantly improve the cognitive function.
